Encapsulating peritoneal sclerosis (EPS) is drawing attention to the PD community because of its unpredictable onset and high mortality.Recently, the Scottish Renal Registry [1] has established the incidence of EPS and its correlation with PD duration in that region. The rate of EPS among patients on PD was 1.5%, with an incidence of 4.9 per 1,000 person-years. This rate is well within those reported previously (0.7-3.3%) [2][3][4][5][6][7]. Interestingly, the EPS rate increased with longer duration of PD up to 5 years (from 0% at\1 year to 8.8% at[5 to 6 years), and then decreased (5% at[6 years). The median duration of PD before EPS developed was 5.1 years. At the time of diagnosis only 26% of patients with EPS were on PD. In the remainder (74%), EPS was diagnosed after PD had been discontinued; 50% of them were diagnosed with EPS after kidney transplantation with calcineurin inhibitor-based immunosuppression.